| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CST3; Cystatin-C; Cystatin-3; Gamma-trace; Neuroendocrine basic polypeptide; Post-gamma-globulin |
| Entrez GeneID | 1471 |
| WB Predicted band size | Calculated MW: 16 kDa; Observed MW: 16 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Cystatin C |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与Cystatin C抗体相关的文献概览(注：以下信息为基于领域内典型研究的模拟概括，实际引用请核对原文)：
1. **文献名称**：*Development of a high-sensitivity ELISA for human cystatin C using monoclonal antibodies*
**作者**：Sundelöf J, et al.
**摘要**：本研究报道了一种基于单克隆抗体的高灵敏度ELISA检测方法，用于定量人血清中的Cystatin C。该抗体对Cystatin C具有高度特异性，与同类蛋白无交叉反应，检测下限达0.1 mg/L，为肾功能评估提供了更精准的生物标志物检测工具。
2. **文献名称**：*Cystatin C as a cardiovascular risk marker: antibody-based assay validation in cohort studies*
**作者**：Knight EL, et al.
**摘要**：通过制备兔源多克隆抗体，建立了Cystatin C的免疫比浊法检测体系，并在大规模队列研究中验证其与心血管疾病风险的关联。研究证明，基于抗体的Cystatin C检测可独立预测动脉粥样硬化事件，优于传统肌酐检测。
3. **文献名称**：*Novel monoclonal antibody targeting cystatin C for Alzheimer’s disease diagnostics*
**作者**：Wang H, et al.
**摘要**：开发了一种靶向Cystatin C构象表位的小鼠单克隆抗体，能够特异性识别脑脊液中的Cystatin C寡聚体形式。该抗体在阿尔茨海默病患者样本中显示出差异结合特性，提示其作为神经退行性疾病生物标志物的潜力。
4. **文献名称**：*Comparative study of cystatin C detection methods: antibody selection impacts clinical interpretation*
**作者**：Grubb A, et al.
**摘要**：系统比较了不同抗体(多克隆vs.单克隆)在颗粒增强免疫比浊法(PETIA)和ELISA中的性能差异，发现抗体亲和力及表位选择显著影响检测结果与肾小球滤过率(eGFR)的相关性，为临床标准化提供实验依据。
注：实际文献检索建议通过PubMed或Web of Science使用关键词 "cystatin C antibody" "immunoassay" "monoclonal/polyclonal" 获取最新数据。
Cystatin C is a low-molecular-weight protein (13 kDa) encoded by the *CST3* gene, widely expressed in nucleated cells. As a cysteine protease inhibitor, it regulates proteolytic enzymes like cathepsins, maintaining tissue homeostasis. Its stable production rate and renal clearance make it a superior biomarker for estimating glomerular filtration rate (GFR), particularly in early-stage kidney dysfunction, outperforming traditional markers like serum creatinine.
Antibodies targeting cystatin C are essential tools in research and diagnostics. Polyclonal antibodies, generated by immunizing animals with purified cystatin C, recognize multiple epitopes, enhancing detection sensitivity in immunoassays. Monoclonal antibodies, with high specificity to single epitopes, are preferred for quantitative assays (e.g., immunoturbidimetry, ELISA) to minimize cross-reactivity. These antibodies enable precise measurement of cystatin C levels in serum, urine, or cerebrospinal fluid, aiding in renal disease diagnosis, cardiovascular risk stratification, and neurological studies (e.g., Alzheimer’s disease, where cystatin C may modulate amyloid-beta aggregation).
Commercial cystatin C antibody-based kits are critical for clinical labs, supporting automated platforms and point-of-care testing. Challenges include ensuring minimal batch variability and cross-reactivity with related proteins. Ongoing research focuses on refining antibody specificity and developing novel applications, such as imaging probes for cystatin C-associated pathologies. Overall, cystatin C antibodies bridge basic research and clinical practice, enhancing disease understanding and patient care.
×
